Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

618.25INR
22 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
Rs618.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,859,343
52-wk High
Rs673.00
52-wk Low
Rs366.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.51
Market Cap (Mil.): Rs496,968.19
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.32

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.74 37.83 38.47
EPS (TTM): 14.15 -- --
ROI: 11.02 18.99 18.25
ROE: 11.10 19.75 19.13
Search Stocks

Novartis sues Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI, Dec 17 - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

BRIEF-Meda and Cipla sue Apotex to enforce Dymista patents

* Meda and cipla sue apotex to enforce dymista patents Link to press release: http://news.cision.com/meda/r/meda-and-cipla-sue-apotex-to-enforce-dymista--patents,c9690543 Further company coverage:

03 Dec 2014

Cipla to market Serum Institute's paediatric vaccines in Europe

MUMBAI - Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.

20 Nov 2014

India's Cipla to market Serum Institute's paediatric vaccines in Europe

MUMBAI, Nov 20 - India's Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.

20 Nov 2014

Cipla down after sluggish exports hit earnings

Reuters Market Eye - Cipla falls 2.39 pct after July-Sept earnings. The drugmaker's Q2 profit fell 16 pct to 2.99 billion rupees ($48.6 million) on sluggish exports.

14 Nov 2014

MARKET EYE -Cipla edges lower after sluggish exports hit earnings

* Cipla falls 0.4 pct after July-Sept earnings. * Drugmaker's Q2 profit fell 16 pct to 2.99 billion rupees ($48.6 million) on sluggish exports. * Export sales in the quarter fell by 4.6 percent. - Company presentation. * Exports mainly hit by higher captive consumption of raw materials, more focus on integration into new markets - Analysts ($1 = 61.5900 Indian rupee) (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

14 Nov 2014

UPDATE 2-India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

* Sun Q2 profit up 15 pct, roughly in line with street estimates

13 Nov 2014

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

30 Oct 2014

Earnings vs. Estimates

Search Stocks